An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody disclosed herein has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present disclosureis useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
